{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:58:15Z","timestamp":1785355095432,"version":"3.55.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"45","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Norman Bethune Specialized Research Fund","award":["HSKY-021"],"award-info":[{"award-number":["HSKY-021"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,7]]},"abstract":"<jats:p>\n                    Elderly non-small cell lung cancer (NSCLC) patients do not always benefit from standard treatments due to impaired organ function and\/or multiple comorbidities. Our study aimed to determine the efficacy and safety of aumolertinib as a first-line therapy in NSCLC patients aged \u226565 and &lt;65 years in clinical practice.We enrolled 100 patients with stage IIA\u2013IVB epidermal growth factor receptor-mutant NSCLC who received aumolertinib alone as the first-line therapy. Efficacy and safety were compared between patients aged \u226565 and &lt;65 years in different subgroups. The primary endpoint was the objective response rate (ORR). The secondary endpoints included progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and safety.Overall, ORR and DCR were 76% and 98%, respectively. ORR was 69.4% and 82.4% for patients aged\u2005\u2265\u200565 and\u2005&lt;\u200565 years, respectively (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.27), and DCR was 98% and 98%, respectively (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.93). The median PFS was 23.2 months. The median PFS was 26.9 months and 18.3 months in the \u226565 and &lt;65 years groups, respectively (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.377, and the median OS of all patients was 31.7 months. The median OS was 33.7 months and 30.7 months in the \u226565 and &lt;65 years groups, respectively (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.851). Adverse events were not statistically different between the 2 groups.The efficacy and safety profile of aumolertinib as a first-line therapy in elderly patients with epidermal growth factor receptor-mutant NSCLC were similar to those observed in the younger subgroup.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000045702","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T18:00:40Z","timestamp":1762538440000},"page":"e45702","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Real-world study of first-line therapy with aumolertinib for elderly patients with non-small cell lung cancer harboring EGFR mutation"],"prefix":"10.1097","volume":"104","author":[{"given":"Na","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Nanjing Chest Hospital, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nanjing Chest Hospital, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwen","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nanjing Chest Hospital, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nanjing Chest Hospital, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hehui","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nanjing Chest Hospital, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyue","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nanjing Chest Hospital, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangfeng","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nanjing Gaochun People\u2019s Hospital, Nanjing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shencun","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nanjing Chest Hospital, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260729","first-page":"115","article-title":"Cancer statistics in China, 2015.","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"R2-20260729","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","article-title":"Cancer statistics in China and United States, 2022: profiles, trends, and determinants.","volume":"135","author":"Xia","year":"2022","journal-title":"Chin Med J (Engl)"},{"key":"R3-20260729","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1016\/j.cllc.2023.06.010","article-title":"Pembrolizumab alone or with chemotherapy for 70+ year-old lung cancer patients:a retrospective study.","volume":"24","author":"Blasi","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"R4-20260729","first-page":"2593","article-title":"Prognostic factors for risk stratification of adult cancer patients with chemotherapy-induced febrile neutropenia: a systematic review and meta-analysis.","volume":"10","author":"Lee","year":"2012","journal-title":"JBI Libr Syst Rev"},{"key":"R5-20260729","article-title":"Investigating the association between advanced practice providers and chemotherapy-related adverse events in women with breast cancer: a nested case-control study [published online ahead of print October 10, 2018].","author":"Yen","journal-title":"J Oncol Pract"},{"key":"R6-20260729","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1200\/JCO.21.02641","article-title":"AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastaticnon-small-cell lung cancer with EGFR Exon 19 deletion or L858R mutations.","volume":"40","author":"Lu","year":"2022","journal-title":"J Clin Oncol"},{"key":"R7-20260729","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jtho.2023.01.088","article-title":"IASLC lung cancer staging project: the new database to inform revisions in the ninth edition of the TNM classification of lung cancer.","volume":"18","author":"Asamura","year":"2023","journal-title":"J Thorac Oncol"},{"key":"R8-20260729","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R9-20260729","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE \u2013 version 5.0) to evaluate the severity of adverse events of anticancer therapies.","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"R10-20260729","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1517\/14656566.2015.1002396","article-title":"First-line gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of North-East Japan Study Group studies.","volume":"16","author":"Morikawa","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"R11-20260729","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"R12-20260729","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"R13-20260729","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1200\/JCO.2007.15.2280","article-title":"Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada clinical trials group study BR.21.","volume":"26","author":"Wheatley-Price","year":"2008","journal-title":"J Clin Oncol"},{"key":"R14-20260729","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1016\/j.cllc.2018.03.009","article-title":"Afatinib as first-line treatment of older patients with EGFR mutation-positive non-small-cell lung cancer: subgroup analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 trials.","volume":"19","author":"Wu","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"R15-20260729","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.lungcan.2021.02.025","article-title":"Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050).","volume":"154","author":"Cheng","year":"2021","journal-title":"Lung Cancer"},{"key":"R16-20260729","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer.","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"R17-20260729","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC.","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"R18-20260729","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S2213-2600(22)00168-0","article-title":"Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study.","volume":"10","author":"Shi","year":"2022","journal-title":"Lancet Respir Med"},{"key":"R19-20260729","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S2213-2600(23)00183-2","article-title":"Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study.","volume":"11","author":"Lu","year":"2023","journal-title":"Lancet Respir Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045702","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:00:27Z","timestamp":1785351627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":19,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045702","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"2024-06-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}